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While the role of the blood-brain barrier (BBB) is
increasingly recognized in the (development of treatments
targeting neurodegenerative disorders, to date, few strategies
15 exist that enable drug delivery of non-BBB crossing molecules
directly to their site of action, the brain. However, the recent
advent of Nanomedicines may provide a potent tool to
implement CNS targeted delivery of active compounds.
Approaches for BBB crossing are deeply investigated in
20 relation to the pathology: among the main important
diseases of the CNS, this review focuses on the application of
nanomedicines to neurodegenerative disorders (Alzheimer,
Parkinson and Huntington’s Disease) and to other brain
pathologies as epilepsy, infectious diseases, multiple sclerosis,
25 lysosomal storage disorders, strokes.
Introduction
The blood brain barrier (BBB)
The central nervous system (CNS) is protected from toxins and
metabolic fluctuations by barriers, among which the blood-brain
30 barrier (BBB) plays a key role in maintaining homeostasis. The
BBB is composed of four major cellular components, the endothe-
lial cells of the brain capillaries, pericytes, astrocytes, and the base-
ment membrane. Together, they build a functional unit, the
‘Neurovascular unit’, mediating exchange between neurons,
35 capillaries and glia. That way, the BBB supplies the brain with nec-
essary nutrients, glucose and oxygen to sustain normal neural func-
tioning. At the same time, the BBB plays a protective role against
neurotoxic substances. Together, the BBB creates the neural micro-
environment that is crucial for healthy brain function2.
40To fulfill this function, the brain has a very close-packed
microvasculature.74,76 This enables very short distances between
the nearest blood capillary and neuronal cells,99 which allows a
fast delivery of substances after crossing the BBB. Further, the
capillaries in the brain are quite different from capillaries found
45in the peripheral organs. Microvessels of the BBB are formed by
non-fenestrated endothelial cells that contact each other forming
tight junctions (TJs) (or zonula occludens). TJs prevent the pas-
sive diffusion of hydrophilic solutes via paracellular transport, the
transfer of substances from the blood into brain parenchyma by
50passing through the intercellular space between the cells. Thus,
water-soluble substances have to cross the BBB by mechanisms of
transcellular transport that involve active transport via specific
carriers.
In addition, brain capillaries are surrounded by pericytes pro-
55truding into the basement membrane, and astrocytic end feet
encapsulating the surface (Grabrucker et al., 2014). Astrocytes
release inductive signals that regulate the BBB 43 and play a role
in maintaining water, ionic, and amino acid homeostasis within
the CNS.1 With an electrical resistance estimated to be  1500–
602000 Vcm2, brain endothelium possesses a much higher electri-
cal resistance than other systemic endothelia with 3–33 Vcm2
17 further limiting diffusion of certain molecules across the BBB.
However, the BBB is a highly dynamic structure and its forma-
tion, maturity and integrity controlled by a collective action of
65all of its constituents. In addition, neurons have been shown to
release growth or nutritional factors maintaining BBB
functioning.
The consequence of this intricate interplay is a controlled and
restricted transport of molecules across the BBB. Only very small
70(<400 Da) and lipophilic molecules can diffuse through the
BBB, while the crossing of lipid insoluble or larger hydrophilic
molecules is very limited. However, additionally to lipophilicity,
other factors such as the affinity toward available transport system
further control BBB crossing. For example, the transport of glu-
75cose through the BBB is mediated by glucose transporter-1
(GLUT-1).60
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The effectiveness of the BBB function depends on several fac-
tors such as the controlled expression of the major constituents of
TJs, such as occluding proteins and proteins of the claudin fam-
80 ily.2 Further, molecules released during neural activity may act
on receptors and transporters of endothelial cells and/or contact-
ing astrocytes. Examples include neurotransmitters such as gluta-
mate and serotonin, but also calcium, and adrenaline.75 Through
these modulatory agents, several parameters of the BBB such as
85 capillary diameter (and thus local blood flow), expression of spe-
cific transporters, and the tightness of TJs can be regulated (Pep-
piatt et al., 2006; 14,27,47; Zlokovic, 2008). Therefore, disrupted
signaling between endothelial cells, pericytes and/or astrocytes
may affect the integrity of the BBB.9,13,28
90 In addition to regulating exchange of molecules between the
peripheral blood circulation and the brain by its anatomical
properties, the BBB is a metabolic barrier. A variety of degrading
and metabolizing enzymes can be found at the membrane of
brain capillary endothelial cells6,32 along with a large number of
95 transporter proteins that strictly regulate the influx and efflux of
substances.
Taken together, these unique features of the BBB control the
homeostasis of a large variety of molecules in the brain. However,
it is the same features that impose a major obstacle to successful
100 delivery of drugs into the brain. For example, various phase l and
phase ll enzymes of the drug metabolism system have been found
in endothelial cells. The major drug efflux transporters include
P-glycoprotein (P-gp),24 ATP binding cassette (ABC), multidrug
resistance-associated proteins (MRPs) and Breast Cancer resis-
105 tance proteins (BCRP). Although in some conditions such as
trauma, multiple sclerosis and Alzheimer Disease, the anatomical
and functional state of the BBB may be altered, the delivery of
active compounds into the CNS needs effective mechanisms to
facilitate BBB crossing.
110Although other barriers such as the blood-cerebrospinal fluid
(CSF) barrier (BCB) and CSF-brain barrier (CBB) exist, the sur-
face area of the BBB is far greater than the surface area of the
BCB. Thus, the BBB is considered the main site for crossing of
endogenous substances into the CNS. In addition, even despite
115the entrance of a drug into the CSF, it does not necessarily results
in its penetration into the brain parenchyma. The penetration of
substances from CSF to brain parenchyma is facilitated through
diffusion. However, the large distances create a diffusion barrier
that can be referred to as the CSF-brain barrier (CBB). In addi-
120tion to the aforementioned external barriers, after crossing the
BBB, the presence of further internal barriers creates another
obstacle for effective drug delivery, such as fast clearing mecha-
nisms by glial cells.
Mechanism of BBB crossing by endogenous substances
125Despite the restricted transport of molecules across the BBB,
the brain has high demand for energy and nutrients. Therefore,
multiple mechanisms exist that mediate the uptake of specific
endogenous substances. Some of these provide a useful basis also
for the development of strategies for drug delivery. In general,
130under physiological conditions, substances may cross the BBB by
passive diffusion, carrier mediated transport, receptor mediated
transport, and adsorptive transcytosis (Fig. 1).
The possibility for substances to passively cross the BBB by
diffusion is very limited (see above) due to the BBB physiology.
135The exception are lipid soluble small molecules with an molecu-
lar weight of less than 400Da. Uptake of such substances is possi-
ble by lipid-mediated free diffusion across the BBB. In contrast
to diffusion through water, diffusion through lipid membranes is
highly dependent on the correlating features of molecular vol-
140ume, molecular weight, and surface area of a substance.84
High lipid solubility in turn is correlated to low hydrogen
bonding. It has been shown that the
ability of a substance to permeate mem-
branes is decreased by 10-fold with
145each pair of hydrogen bonds.112 This
rule has been confirmed in multiple
studies i.e. investigating BBB transport
of steroid hormones and
oligopeptides.84
150Therefore, the majority of substan-
ces is taken up into the brain by carrier
mediated transport and receptor medi-
ated transport. Here, the structure of
the molecule possesses high affinity for
155specific carriers or receptor found at the
BBB. For example, water-soluble meta-
bolic substrates such as glucose, are
bound by specific transporters, here the
glucose transporter type 1 (GLUT1)
160that, however, has also affinity for other
hexoses, including mannose and galac-
tose.79 Another example is the large
neutral amino-acid transporter type 1
(LAT1), which is a carrier for
Figure 1. Transport pathways across blood brain barrier. Under physiological conditions, substan-
ces may cross the BBB by passive diffusion, carrier mediated transport, receptor mediated transport,
and adsorptive transcytosis.
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165 phenylalanine, but also transports over 10 other large neutral
amino acids and, although with lower affinity, small neutral
amino acids.82 To date, many specific transporters have been
identified. Their exact cellular location at the brain microvascula-
ture and expression level, as well as their selectivity largely deter-
170 mine the kinetics and turnover of the transported substances.
For example, the supply of Glucose for the brain is realized
only by GLUT1. GLUT1 is enriched at the brain microvascula-
ture only at the BBB on both luminal and abluminal membranes.
This expression patterns enables not only uptake of Glucose from
175 the blood into epithelial cells but indeed transport across the cells
of the BBB. Due to the high energy - demand of the brain, the
abundance of GLUT1 at the microvasculature is high, relative to
other transporters, which enables rates of glycolysis in the brain
that are over 100-fold greater than rates of amino-acid incorpo-
180 ration into brain proteins.83 However, due to the demand of car-
riers, the process of carrier mediated transport of a substance
across the BBB is saturable.
Carrier mediated transport is not only responsible for uptake
of substances into the brain, but a process that regulates homeo-
185 stasis in bi-directional manner. To that end, active efflux trans-
porters can be found at the BBB that mediate the asymmetric
efflux of metabolites from the brain back to the blood circulation.
It is also these transporters that impose an obstacle to drug deliv-
ery into the brain. The classical active efflux transporter system
190 within the BBB is P-glycoprotein (P-gp). This protein is encoded
by the multidrug resistance gene 1 (MDR1) and its functional
complex is not only modified by internal factors but also environ-
mental clues such as the presence of toxins.30
Receptor mediated transport processes additionally occur at
195 the BBB as mechanism regulating the crossing of endogenous
substances. These peptide receptors may mediate processes such
as transcytosis of ligands from blood to brain or from brain to
blood, or only uptake into the brain capillary endothelium with-
out further export into the brain parenchyma. Well investigated
200 examples include the transport of insulin or transferrin. Insulin is
transported across the BBB by binding to an endogenous BBB
insulin receptor.81 Similarly, for transferrin (Tf) a specific recep-
tor, the Tf receptor (TfR) can be found at the BBB.80 Similar to
carrier mediated transport, the cellular location and expression
205 levels of the receptors determine the kinetics and turnover of the
transported substances. For example, the TfR mediates influx of
holo-transferrin from blood to brain but also reverse transcytosis
of apotransferrin from brain to blood due to expression on the
luminal and abluminal membrane of the capillary
210 endothelium.108,130
Finally, a mechanism of BBB crossing called adsorptive endo-
cytosis has been described. This process requires an interaction
between a ligand, such as a macromolecule or protein in the
bloodstream and the cell surface. This interaction may be trig-
215 gered by an electrostatic interaction between the positively
charged ligand and negatively charged plasma membrane. Ulti-
mately, this may result in adsorptive transcytosis of the ligand,
which is mediated by clathrin-dependent endocytosis in most
cases. This mode of BBB crossing seems to occur only unidirec-
220 tional, from blood to brain. Adsorptive transcytosis has been
described for some compounds and Nanoparticles (NPs). How-
ever, whether adsorptive transcytosis contributes significantly to
the transport of endogenous substances across the BBB is still
under investigation.119
225Several of the mechanisms involved in BBB crossing of endog-
enous substances can be used for the development of strategies for
drug delivery. For example, delivery of drugs that have structures
that mimic the endogenous substrate of transporters at the BBB
may be facilitated. The vast majority of carrier mediated trans-
230port systems has been identified and transporters can be expressed
in in vitro systems to screen for drugs that have an acceptable
affinity for a given BBB transporter. A drug that shows such an
affinity for a carrier mediated transport system is L-DOPA. L-
DOPA is used in the treatment of Parkinson Disease and is a
235dopamine precursor that is transported across the BBB via the
LAT1 carrier.55 Alternatively, drugs might be conjugated to sub-
stances that normally cross the BBB by carrier mediated pro-
cesses. Further, the presence of endogenous receptors with
specific ligands triggering BBB crossing mechanisms, such as the
240insulin receptor or the TfR, enables the engineering of peptides
that attached to compounds or drugs mimic these ligands.
However, after successful crossing of the BBB, most drugs are
taken up by cells. A major pathway mediating this uptake is cla-
thrin-dependent endocytosis. This mode of uptake leads to the
245eventual delivery of substances into the endo-lysosomal compart-
ments. Due to the low pH and the presence of degrading
enzymes in lysosomal compartments, delivered biomolecule may
be degraded creating a major obstacle in the delivery of active
compounds, in particular of therapeutic proteins.
250Thus, taken together, there is an urgent need to develop new
strategies for the effective delivery of substances across the BBB.
Therapeutic compounds need to be protected from degrading,
metabolizing and inhibiting processes within the blood stream,
need to be taken up into the CNS via the BBB with high effi-
255ciency, and need to be targeted to specific sites of action prevent-
ing lysosomal degradation. Here, Nanomedicines provide major
advantages compared to common drug delivery systems
Nanomedicines
In this review, we would like to summarize the most interest-
260ing applications of the last 20 y of nanoparticles and liposomes
in in vivo Brain experiments. Considering the variability of in
vivo models, we skip to review the “proof-of-concept,” but
mainly focusing on “In vivo disease models.” The “In vivo disease
models” describes the application of nanoparticles and liposomes
265in brain pathology, pointing the critical attention on the animal
models of pathology and on the possible mechanism involvement
in the treatments. This section is divided into two main under-
chapter: “Neurodegenerative Diseases” and “Other Brain Patho-
logies.” In “Neurodegenerative pathologies” section, we include
270Alzheimer, Parkinson and Multiple Sclerosis diseases. Finally, in
“Other Brain Pathologies” section we include some of the most
relevant papers on convulsive models, stroke, brain infectious dis-
eases and prion diseases.
www.tandfonline.com e1153568-3Tissue Barriers
Firstly, we have to stress the difficulty to identify a “standard”
275 in vivo model for each disease, thus the possible meta-analysis of
the data, which could help the neuroscientist in the basic
research, is virtually impossible. In particular, to our best knowl-
edge, in almost all neuro-pathologies conditions (such as Parkin-
son disease, HIV-dementia and some infectious brain diseases),
280 the BBB permeability is seriously compromised, while in other
brain diseases (stroke and brain tumors, as examples), the BBB
integrity appears to be seriously damaged. As example, we must
consider that the use of brain tumors (namely, gliomas) in vivo
application must be thought as “glioma” delivery and not as
285 brain targeting or BBB crossing exploitation, since over the pro-
gression of the pathology, it has been demonstrated that BBB is
losing its integrity.10
Secondly, since this field of science (namely,
“nanoneuroscience” or “neuro-nanomedicine”) is relative new
290 and young, the most of papers are based on “Proof-of-Concept,”
while the application on brain diseases models appears in con-
stant increase, but still lower than the basic research. This evi-
dence could be explained by the fact that a unique carrier for
brain delivery does not exist, since it possible to take advantage of
295 different ligands, receptors and mechanisms for BBB crossing
and brain targeting. Then, the use of different starting polymer
(poly-lactide-co-glycolide, poly-buthyl/heaxil-cyano-acrylate,
albumin, chitosan, and many others) for nanoparticle prepara-
tion or lipid composition (cationic/anionic/neutral, pegylated
300 lipids and many others) for liposome preparation, results in dif-
ferent brain targeting mechanisms, different biodistribution pro-
files, different brain delivery efficacies and overall toxicities.
Notwithstanding all of these differences in animal models and
carriers, with this review, we aimed to produce a useful tool for
305 all the neuroscientist to access a plenary of in vivo evidences.
Nanoparticles and liposomes
Generally talking, polymeric nanoparticles (NPs) are solid col-
loid matrix-like particles sizing from 1 to 1000 nm, made of pol-
ymers of different nature, and encapsulating molecules during
310 the preparation process, chosen depending on both the polymers
and the drug to be delivered. There are several natural or syn-
thetic polymers often mixed during the preparation of NPs, but
considering the stringent request of FDA guidelines in terms of
biodegradability and biocompatibility for in vivo administration,
315 the list of polymers, that could be used to prepare NPs systems,
results very short with few polymers available for drug delivery
system preparation and approved for systemic administration.
Among them, natural (e.g. Albumin) and poly-ester (poly-lactide
and derivatives) polymers are the most accepted. In particular, it
320 is a common opinion that the toxicology of a nanodevice should
be related both to morphological and structural parameters of
the systems (size, surface charge, shape) and the polymers used.
Liposome (LPs) are surely the most studied and old smart sys-
tems, applied in different fields of medicine research, represent-
325 ing the first innovative approach for the treatment of challenging
pathologies, like cancer, HIV, strokes and many other diseases
which require selective therapies.42,68 As described for NPs, LPs
need a surface modification in order to promote specific delivery
and targeting of the embedded drugs. Generally speaking, good
330in vitro results on LPs experimentations do not reflect in vivo
confirmations, leading to a very low applicability of the lipo-
some-approach in the treatment protocols. This event, connected
with a very quick elimination and degradation when LPs are
injected in the bloodstream, along with the type and properties
335of phospholipids which are constituents of the liposomes, was
faced with different strategies such as using stabilizers or modifi-
cation of preparation procedures. Particularly, the conjugation
with molecules, able to protect the LPs from the degradation
(GM1, poloamine, polaxamer and PEG) or able to induce an
340increased affinity to the diseased cells, represented one of the
most applied strategies. The pegylation technology offers a
potential resolution of the problem of liposome’s bio-stability,
connected to the liposomal intravenous administration.50,91
Finally, in order to increase the minimal affinity to the diseased
345cells and to avoid the toxic effect on non diseased tissues, an
active targeting due to functionalization of the surface of the lipo-
some is hardly needed.128
In vivo disease models
If in the previous examples the integrity of the BBB was main-
350tained and the brain was considered as a “non-pathologic” brain,
in the following examples, several researches have been reviewed
concerning neuro-pathologies in which the BBB integrity and
permeability is seriously compromised.12,51,103,135 These pathol-
ogies could vary from neurodegenerative diseases (Parkinson,
355Alzheimer and Huntigton’s) to epilepsy, infectious brain diseases,
strokes and many others.
Neurodegenerative disease
Alzheimer disease
Alzheimer disease (AD) is a chronic and progressive neurode-
360generative disorder that begins with cognitive and memory
impairments, accompanied with behavioral disturbances such as
aggression, depression, hallucination, delusion, anger and agita-
tion and eventually progresses to dementia, physical impairment
and death.26 AD is the most common form of dementia, and the
365greatest risk factor for AD is age. It is estimated that 10% of peo-
ple over the age of 65 are affected by AD 4 and by 2050, the
number of people with AD in the US will increase threefold.45
The definite diagnosis of AD is made upon histological verifica-
tion, established by biopsy or at autopsy, of two main hallmarks:
370extracellular amyloid plaques and intracellular neurofibrillary
tangles, which enclose hyperphosphorylated tau protein.26,102
Furthermore, the neuropathology of AD is characterized by a
progressive loss of synapses and neurons in a region- and cell-
type-specific manner.95 In Alzheimer disease, microglia and
375astrocytes are activated by b-amyloid protein and related oligo-
peptides, leading to a cascade of events producing toxic mole-
cules, neuronal damage, synaptic dysfunction and alteration of
the permeability of the BBB.10
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To study this pathology, a model of acute amnesia is induced
380 in rats or mice by subcutaneous injection of scopolamine.86
These animals are submitted to the passive avoidance reflex
(PAR) test118 to determine the memory changes; the PAR is
based on the measurement of the retention latency times,
necessaries for the animals to avoid a painful stimulus; these
385 latencies are directly proportional to the decrease of amnesia,
thus representing a useful tool to describe the effectiveness of
anti-amnesia drug injected. Kurakhamaeva and colleagues59 used
Nerve Growth Factor (NGF) loaded in PBCA NPs covered with
PS-80 to reduce amnestic effect. With this study, they demon-
390 strated that brain-targeted NPs loaded with NGF allowed an
improvement of amnesia with a significant increase of the latent
period of 2-fold, if compared to animals treated with NGF-free
solution. In another paper, Abdel-Wahab3 demonstrated the effi-
cacy of 2 different systems: PBCA Np covered with polysorbate-
395 80 and PBCA Np covered with PEG5000, both loaded with tac-
rine (reversible inhibitor of acetylcholinesterase) able to improve
cognitive function. These NPs formulations increased the latency
period in treated animals of 1,2-fold and 1,4-fold, respectively,
compared to the injection of tacrine-free solution (Table 1).
400 In our opinion, the greater effect obtained with drug loaded
PBCA NPs covered with PEG5000 as compared to the drug-free
solution and to the drug loaded PBCA-NPs covered with Polisor-
bate-80 could be due to the alteration of the BBB permeability
rather than a specific targeting: in fact, the presence of PEG onto
405 the NPs surface confers stealth properties to the NPs, allowing
them to remain over a longer time in the systemic circulation,
thus improving the chances to reach the pathological site.
Moreover, the role of surfactants (polysorbate 80 as well as
polaxamers or PEG) as possible pathways for BBB permeability
410 increase was deeply debated by several authors, without any effec-
tive and clear result.7,87 The only evidence was achieved by 2-D
electrophoresis (2-D PAGE) showing that PBCA NPs coated
with polaxamer 188 (Pluronic F68) and Ps80 showed a consid-
erable adsorption of apolipoprotein A-I (ApoA-I), leading to a
415 possible interaction with BBB receptors. This finding could
induce to propose a general pathway for BBB crossing of PBCA
coated Ps80 (or Pluorinc), based on a great absorption of APO
A-I allowing a receptor-mediated transcytosis. This hypothesis
cannot be generalized, since it should be taken into consideration
420 the close interaction between polymer and surfactants as well as
the whole NPs interaction with the BBB.
Parkinson disease
Parkinson disease (PD) is a multicentric neurodegenerative
disease. Estimates state that 1% of people over age 60 are affected
425 by PD, the leading cause of the movement disorder called Parkin-
sonism.4 Clinical features of PD include tremor at rest, bradyki-
nesia, rigidity and flexed posture.48
Pathologically, the key deficit in PD has been considered to be
the loss of dopaminergic neurons in the substantia nigra, which
430 causes consequent reduction of dopamine level.98 Cell loss and
Lewy body formation (abnormal intraneuronal aggregates of pro-
tein, predominantly a-synuclein) occur in the locus coeruleus,
dorsal motor nucleus, and substantia innominata.15
Consequently, nor-adrenergic, serotonergic and cholinergic neu-
435rons are also lost and this widespread neurodegeneration leads to
the emergence of a variety of features known as “non-motor”
symptoms in PD that include cognitive decline, apathy, depres-
sion, anxiety disorders, hallucinations, gait and balance distur-
bances, sleep disorders, sexual dysfunction, bowel problems,
440drenching sweats and pain.46 At present, for this pathology no
significant evidences of BBB permeability alteration are
described.
As there is currently no permanent rescue and cure for Parkin-
son disease, and there are no known agents to slow the progres-
445sion of PD, the current treatments are used to decrease the
symptoms of PD.64,122 Although symptomatic therapy of PD is
effective (Levo-Dopa), novel therapeutics are required as well as
advanced delivery methods, as the active substances will need to
enter the CNS to exploit their effects (Table 1).
450Animal PD model is obtained through injection of neurotox-
ins: the most used toxin is 6-hydroxydopamine (6-OHDA ster-
eotaxical injected),16 but also 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP i.p. injected) is used18: both agents
destroy neurons by generating active oxygen species such as
455superoxide radicals. Kurakhamaeva and colleagues59 used mice
treated with MPTP to test the efficacy of NGF entrapped in
PBCA NPs covered with polysorbate-80. This mice were submit-
ted to many tests to evaluate the improvement in Parkinson
symptoms: i) open field test, that allows to check the orientation-
460research reaction; ii) locomotor activity in the actometer, to value
the quality and the quantity of movement; iii) rigidity, through
the registration of the alteration of gain dynamic; iv) tremor,
through the registration of intensity and duration of tremor.
With all these tests, the researchers observed that the administra-
465tion of targeted NPs allowed a significant improvement in PD
symptoms already after 90 minute and maintained for 21 day.
The research group of Pardridge performed several studies
using rodents 6-OHDA treated with apomorphine or amphet-
amine to induce rotation: the reduction in the number of rota-
470tions, promoted by administration of anti-parkinson drugs,
demonstrated a improvement in PD induced syndrome. In fact,
Xia and co-worker126 prepared a LPs formulation loaded with
GDNF plasmid (Glial-derived neurotrophic factor) and targeted
to the brain with OX-26 (mAb against the mouse TfR). The sin-
475gle administration of that system to 6-OHDA rat treated with
apomorphine, showed a general improvement of PD symptoms,
as they observed a decrease in rotational behavior of 58% and a
great increase of Tyrosine Hydroxylase (TH) activity as com-
pared with saline control. In another paper, Zhang and colleagues
480improved the results obtained by Xia, using a multiple injection
of the LPs,132 achieving a decrease in the rotational behavior until
90% and an increase in the TH activity until 77%, compared
with saline control. Besides, Zhang performed another test,
namely the Vibrissae-Elicited Forelimb Placing Test, aiming to
485evaluate the forelimb response to ipsilateral facial whisker stimu-
lation8 This test showed an improvement of response up to 4-
fold, if compared to saline control, thus allowing the authors to
corroborate the results obtained before. In another article,131
Zhang showed the results obtained with the same kind of
www.tandfonline.com e1153568-5Tissue Barriers
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490 targeted LPs loaded with 877 cDNA (a cDNA of TH gene). It
was seen that the LPs, administered at a different dose of loaded
drugs, allowed a decrease in rotational behavior of 70% until
3 day post injection, but after 6 d the TH enzyme activity
decreased and after 9 d it was comparable to the control. Xia and
495 colleagues, in a following article,127 demonstrated that the incor-
poration of a TH plasmid in the same targeted systems can allow
a prolongation of the neuroprotective effect but, unfortunately,
without showing the effect 3 d after the injection.
Haloperidol and chlorpromazine were also used to induce
500 extra pyramidal effects in rat or mice. In particular, Pichandy and
colleagues88 treated rats with haloperidol to test the anti-PD
effect of Dopamine loaded in LPs formulated with the use of
span 80 and tween 80. Both formulations allowed an increase in
muscular coordination activity, tested with the rotarod test, along
505 with in locomotor activity, tested with actophotometer. On the
contrary, Jain and coworkers,53 took advantage of rats, injected
with chlorpromazine (inducing catatonia) to test non targeted
LPs loaded with dopamine, showing a complete reduction of cat-
atonia state in the 83% of animals treated 150 min after
510 injection.
Huntington’ s disease
Huntington’s disease (HD) is a genetic neurological disorder
caused by a CAG expansion in the gene encoding the huntingtin
(HTT) protein. HD is featured by motor, cognitive and psychi-
515 atric disturbances, neuronal dysfunction, atrophy of the striatum
and other brain regions, and progressive loss of striatal medium-
sized spiny neurons (MSNs) and of cortical pyramidal neurons
(Vonsattel et al 1998). Several molecular and cellular dysfunc-
tions have been identified (Zuccato et al 2010) and one affected
520 pathway implicates brain cholesterol. Brain cholesterol biosyn-
thesis and cholesterol level are reduced in Huntington’s disease
(HD) mice suggesting that locally synthetized, newly formed
cholesterol is less available to neurons. This might be detrimental
for neuronal function, especially given that locally synthesized
525 cholesterol is implicated in synapse integrity and remodeling.
Biodegradable and biocompatible polymeric nanoparticles (NPs)
modified with glycopeptides (g7) and loaded with cholesterol
(g7-NPs-Chol), which per se is not blood-brain barrier (BBB)
permeable, were successfully apply in order to obtain high rate
530 brain delivery after intraperitoneal injection in HD mice. g7-
NPs, in contrast to unmodified NPs, efficiently crossed the BBB
and localized in glial and neuronal cells in different brain regions.
We also found that repeated systemic delivery of g7-NPs-Chol
rescued synaptic and cognitive dysfunction and partially
535 improved global activity in HD mice.116
Multiple sclerosis
Multiple Sclerosis (MS) is a disorder of the CNS with inflam-
matory and neurodegenerative components, and characterized by
a variable clinical pattern, which ultimately leads to a progressive
540 neurological dysfunction.63 Its pathological hallmarks are demye-
lination and cellular infiltration of T cells and macrophages (Mf).
Despite long-term immunotherapy, relapses occur, which are
commonly treated by repeated i.v. injections of high dose (pulse)
glucocorticosteroids (GS) as a potent antiinflammatory drug
545(Table 1).
The most applied in vivo experimental model of MS is the
experimental autoimmune encephalomyelitis (EAE) with a high
tissue inflammation and the partial disruption of the BBB.73,115
Considering MS-diseased BBB, it has been shown that disease
550severitiy could be correlated with alteration of BBB integrity, as
confirmed by loss and delocalization of brain endothelilal junc-
tion proteins, like occluding., VE-cadherin and others.67,123
Schmidt and co-workers, in two different works, 100; 2003b)
demonstrated that long-circulating prednisolone LPs (PL) were
555able to localize the high tissue therapeutic levels of glucocortical-
steroid in the inflamed cerebral area of autoimmune EAE rats
model39 as compared with an equivalent dose given as free drug
with a following reduction of inflammation and a significantly
improvement in the disease course of (AT)-EAE. Moreover, the
560drug targeting by LPs appears highly effective in restoring the
BBB integrity, ameliorating the disease activity of active and
adoptive transfer (AT)-EAE without detectable side effects. The
authors hypothesized a selective targeting, but in our opinion the
altered permeability of BBB surely increases the penetration and
565the localization of LPs in inflamed tissue. Similarly, Kizelsztein at
al.56 demonstrated the ability of long-circulating LPs to transport
a potent antioxidant (Tempamine,TMN) to the brain tissue in a
concentration able to significantly attenuate clinical symptoms of
EAE in the mouse model.89 The authors hypothesized that the
570size and the long circulation properties of these LPs could pro-
mote their extravasation into a well permeable inflammation
sites.
Other brain pathologies
575Epilepsy
Epilepsy is defined as a condition characterized by recurrent
(two or more) epileptic seizures, unrelated to any immediate
identified cause44 Epilepsy is one of the oldest known conditions
to mankind and still the most common neurological condition
580affecting individuals of all ages. At any given time, it is estimated
that 50 million individuals worldwide have a diagnosis of epi-
lepsy124 ; 2001b). Recently an excellent descriptive review con-
cerning the epidemiology of epilepsy was published.11 Several
evidences demonstrated that the epileptic seizures alter blood-
585brain barrier (BBB) properties and permeability.31,54,117 Particu-
larly, a recently in vivo study demonstrated the dynamic changes
of BBB permeability during epileptogenesis. The long-lasting
increased permeability of the BBB indicated that it may contrib-
ute to increased excitability in the epileptogenic foci, leading to
590the progression of epilepsy and seizure development.117 Consid-
ering the application of drug delivery systems as a treatment strat-
egy in epilepsy (Table 2), Mori and coworkers, in two different
papers, compared the anticonvulsivant effect of valproic acid and
g-butyrolactone-g-carbonyl-L-histidyl-L propynamide citrate
595(DN-1417) entrapped in LPs with that obtained after free drug i.
v. administration in amygdaloid-kindled rats70; 1992b). The ani-
mal models were obtained implanting a bipolar electrodes in the
right area amygdalaris anterior that are stimulated at a defined
e1153568-8 Volume 4 Issue 1Tissue Barriers
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time intervals and frequency as described by L€oscher and co-
600 workers.62 In all cases, while the administration of free drug sup-
pressed amygdaloid kindled seizure for few time, the drug encap-
sulated in positive charged LPs showed a prolonged anti-
convulsivant effect. The authors hypothesized that LPs protected
the drug from the enzymatic degradation and that LPs surface
605 charge played an important role in allowing the rapidly cross of
the BBB, by taking advantage of adsorbtive-mediated endocyto-
sis. Recently, the same group of research evaluated the effect of
phenytoin (PHT), entrapped in LPs (PHT-LPs), on the status
epilepticus, induced in rats by injecting a combination of dibu-
610 tyryl-cAMP (db-cAMP) and ethylenediaminetetraacetic acid
(EDTA) into the amygdala (AM).
The researchers observed the suppression of AM discharges by
two injections of PHT-L. The authors hypothesized that the AM
epileptogenic focus created by db-cAMP/EDTA has a high affin-
615 ity for LPs, and this factor participates in the local suppression of
AM discharges by PHT-L. Even if, the mechanism underlying
the selective augmentation of LPs in the epileptogenic AM is not
known, the amount of LPs in the circulation may be important
for the understanding of this finding, since two injections of
620 PHT-L caused preferential suppression of AM discharges as well
as two injections of horseradish peroxidase (HRP; to which the
blood-brain barrier is impermeable) loaded LPs increased their
augmentation in the AM. Since, the blood flow is reliably
increased in the epileptogenic focus, it is our opinion that the
625 possible cause of LPs local augmentation could lie in the blood-
flow increase, along with the permeability of BBB increasing over
the disease progression, consequently promoting the brain locali-
zation of LPs (Mori et al., 1995).
Friese and coworkers evaluated the prevention of maximal
630 electroshock induced convulsions in mice model after i.v. admin-
istration of a novel non-competitive NMDA receptor antagonist
MRZ 2/576 (potent but rather short-acting anticonvulsant, rap-
idly discharged from the central nervous system by transport pro-
cesses that are sensitive to probenecid) bound to PBCA NPs
635 coated with PS-80; this formulation prolonged the length of the
anticonvulsive effect up to 210 min and after probenecid pre-
treatment up to 270 min compared to 150 min with probenecid
and MRZ 2/576 alone.36 Reasonably, the NPs operated as drug
delivery systems, able to protect and to prolong the release of
640 drugs to the CNS. Moreover, the coating of NPs with PS-80
seems to be necessary to target and to achieve an uptake of the
particles into the brain. It is also important to consider that the
BBB properties can be altered by the treatment performed to
achieve animal model, thus promoting and enhancing NPs BBB
645 crossing.
Lysosomal storage disorders
The lysosomal storage diseases (LSDs) are a heterogeneous
group of disorders that affect 1/7,000 live-born infants, the
majority of which develop CNS disease. Each LSD results from
650 a deficiency of a single lysosomal enzyme, pivotal for degrading
macromolecules that must be turned over in lysosomes.110 More
than 40 LSDs have been described. The neurological compromis-
sion is generally refractory to treatment, which will require long-
term correction of lesions dispersed throughout the central ner-
655vous system to be effective. A promising approach is enzyme
replacement therapy (ERT) or gene therapy by gene transfer
methods enable the treatment of these diseases by transferring a
wild-type copy of the gene of interest to some target organ, where
the production and export of the protein proceed for extended
660periods of time.109 In this contest, Zhang and co-workers133
treated a mice model for type VII mucopolysaccharidosis (MPS-
VII), deficient for the b-glucuronidase (GUSB) lysosomal
enzyme, with GUSB expression plasmid (p-CMV GUSB) encap-
sulated in LPs and superficially engineered with the rat
6658D3 MAb to the mouse transferrin receptor (TfR) to achieve
BBB crossing Q3(Table 3). The results demonstrated that sub-nor-
mal, yet therapeutic levels of GUSB enzyme activity, are achieved
in brain following the i.v. administration of the TfR mAb-tar-
geted LPs encapsulating p-CMV GUSB plasmide. This kind of
670strategy, even if interesting, will required repeat administrations,
considering the chronic progression of disease and the inability of
the plasmid delivered by LPs to integrate into the host genome.21
Stroke
After heart disease and cancer within the developed world,
675stroke is the third largest killer, second most common cause of
neurologic disability after AD.78 There are over five million
deaths/year from stroke and over nine million stroke survivors.
Between the ages of 45 and 85, 20-25% of men and women,
respectively, can expect to have at least one incident of stroke.
680Atherosclerosis, heart disease, hypertension, diabetes, and life-
style habits are risk factors correlated with disease. Unlike AD
and PD, many of the risk factors for developing this disease can
be modified. The etiology of stroke is brain vascular occlusions
(thrombotic stroke) or rupture (hemorrhagic stroke). The neuro-
685pathological hallmarks of stroke are necrotic infarcts of variable
size with inflammatory gliosis.
The effect of hypoxia-ischemia on the BBB has been exten-
sively investigated57; Bolton et al., 1998;34,65: this disease sets in
motion a series of events, which leads to disruption of TJ and
690increased BBB permeability, probably mediated by cytokines,
VEGF, and NO. Moreover, elevated levels of proinflammatory
cytokines, IL-1b, and TNF-a have been demonstrated in animal
brains after focal and global ischemia33 and in cerebrospinal fluid
of stroke patients.114
695The potential of LPs and NPs in protecting and modulating the
delivery of un-stable drug during the ischemic insult was deeply
investigated in several researches with interesting positive results
(Table 2): the success of the use of nanocarriers is not to be corre-
lated to the need of an active targeting, but better to the facilitate
700diffusion of these systems through the compromised and broken
BBB. LPs and NPs were used to deliver drugs able to prevent ische-
mic neuronal damage. Several researchers used rats as animal mod-
els, in which the focal cerebral ischemia was produced by the
method described by Chen and colleagues20 based on an extensive,
705but reproducible infarct. In an old study, Chan and coworkers19
described the ameliorated condition of animals manifesting the
reduction in brain level of superoxide radicals when treated with
superoxide dismutase (SOD) loaded into LPs. This success could
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be firstly searched both in the protection exploited by LPs along
710 with their ability to operate a prolonged delivery of drug. More
recently, Imaizumi and co-workers, using the same animal model,
demonstrated that LPs facilitate the delivery of SOD, thus elevat-
ing SOD activities into the brain, not only in the infarct, but also
in the non-infarcted subcortical areal. The authors try to justify
715 these results hypothesizing the penetration of SOD loaded LPs
across the leaky BBB in the ischemic zone and subsequently LPs
uptake by adjacent neurons and microglia extending the area of
action; otherwise, SOD loaded LPs could exert their action on
extracellular superoxide on the luminal side of capillaries, without
720 penetrating the BBB.49 More recently, Reddy and coworkers dem-
onstrated the ability of PLA NPs to encapsulate and to stabilize
SOD from degradation and to provide a localized modulated brain
delivery that assures the protective effect of the enzyme by neutral-
izing the deleterious effect of reactive oxygen species which are the
725 mediators of reperfusion injury.90 By using focal cerebral ischemia
model rats, Sopala and co-workers111 evaluated the neuroprotec-
tive activity of the novel glycine-b site NMDA (N-methyl-D-
aspartate) receptor antagonist MRZ 2/576, formulated in NPs
that provide a system able to protect and to modulate the delivery
730 of the drug to the CNS.
In another study, citicoline-loaded LPs were administered in
ischemic reperfused mice; the LPs formulations produced an
increase in rat survival rate of about 24% and a reduction of 60%
in diene levels (index of lipid peroxidation) compared to the free
735 drug.35 Yokota and colleagues (Yokota et al., 1999) administered
a calpain inhibitor to gerbils to rescue ischemic neuronal damage,
but with a little beneficial effect due to BBB crossing inability of
the inhibitor. On the contrary, the calpain inhibitor-LPs complex
was able to produce a potently and selectively inhibition of cal-
740 pain activation. LPs protect the drugs and maintain a higher con-
centration in the brain than free drug.
Querciein is an interesting herbal compound that exhibits anti-
oxidant properties against many neurological diseases. Initially,
Das and coworkers29,97 proposed the use of LPs encapsulating
745 quercetin, administered i.v. to rats (pre-treated with arsenic) as a
good formulation to attenuate the oxidative damage induced by
ischemia reperfusion injury in the rat brain. Recently, they pro-
posed the use of PLGA NPs as quercitin carriers in combating
arsenic induced oxidative damage in brain of rats. A singular dose
750 of sodium arsenite was sub-cutaneously injected in rats to obtain a
model of arsenic toxicity. Nanoencapsulated quercitin, orally
administered before the arsenite injection, prevented the arsenic
cerebral oxidative damage.38 The authors hypothesized the ability
of these NPs to cross the BBB via particle uptake mechanism
755 based on an endocytotic pathway by the brain capillary endothelial
cells. It is not clear if the treatment of rats with arsenic maintained
the BBB integrity, thus it is difficult to give an absolute conclusion
on the real efficacy and BBB crossing pathway. The increased effi-
cacy of these formulations should be found in their ability to stabi-
760 lize the drug and to prolong the brain delivery.
Traumatic brain injury
Traumatic brain injury (TBI), happens when an external force
traumatically injures the brain. TBI can be classified on severity,
mechanism (closed or penetrating head injury) and area (specific
765or widespread area). TBI is now considered as one the major
major causes of death and disability worldwide, especially in chil-
dren and young adults.. It could vary on severity depending on
the casues, but the common features are mainly consiting on
alterations in cerebral blood flow and the pressure within the
770skull, contributing substantially to the damage from the initial
injury. In this kind of pathology, blood-brain barrier features are
strongly altered, as permeability and transport across the BBB are
dramatically changed.
Several attempts in prevention and “quick” interventions were
775performed in the past years, also dealing with nanomedicines,
able to transport and deliver efficiently in the traumatic areas
those drugs needed to restore “altered” parameters.105,107
In particular, a recent study69 demonstrates that the adminis-
tration of polyamidoamine (PAMAM) dendrimers could be
780taken up in the brain of injured animals and selectively localize
in the injured neurons and microglia in the brain. Besides, these
dendrimers were also able to deliver two clinically approved
drugs, N-acetyl cysteine (attenuating neuroinflammation) and
valproic acid (attenuating excitotoxicity), building on positive
785outcomes in a rabbit model of perinatal brain injury.
In another elegant research,96 self-assembling peptide nano-
fiber scaffold were used to reduce acute brain injury and brain
cavity formation, and to improve sensorimotor functional recov-
ery. SAPNS serves as biocompatible material in the hemorrhagic
790brain cavity. Local delivery of this nanomaterial may facilitate the
repair of ICH related brain injury and functional recovery.
Besides, in another paper,25 the impact on the size of nanome-
dicines (pegylated PLGA NPs sizing 100nm, 200 nm and
800nm) on distribution in TBI animal models was studied. The
795results highlighted that smaller NPs are facilitated in BBB cross-
ing while bigger NPs may result in a lower permeation. This
finding would be extremely important in order to understand the
rationale in planning nanomedicine for this kind of interventions
and may help in designing NPs with a higher performance in tar-
800geting traumatic brain areas depending on the size and on the
BBB permeability under TBI events.
In the treatment of TBI, the use of mixture of peptides acti-
vating growth factors was deeply studied in the last 5 y106 Cere-
brolysin is a peptide mixture able to ameliorate symptomatology
805and to delay progression of neurological disorders such as Alz-
heimer disease and dementia. Cerebrolysin loaded PLGA NPs
were therefore designed, formulated, tested on stability over time
in plasma and finally in animal models, where they were able to
deliver cerebrolysin to reduce brain pathology following trau-
810matic brain injury.94
Infectious disease
Brain inflammatory diseases such as meningitis and encephali-
tis are among the top ten infection causes of death; they are
caused by bacteria (such as Bacillus anthrax, Staphylococcus
815aureus), fungi (ex Candida albicans, Cryptococcus neoformans)
or viruses (Jafari et al. 1994;77,93 Despite the general efficacy of
antibiotic treatment, high mortality and morbidity is frequently
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recovered due to the difficulty of drugs to the BBB and access the
brain (Table 3).
820 The LPs approach in brain infectious therapy could be mainly
refereed to the use of Ambisome

, a liposomal formulation of
amphotericine B in which the drug is strongly associated with the
bilayer structure of unilamellar LPs.
Several works, using different animal models, provided evi-
825 dences of AmBisome effectiveness against brain infections. Groll
and colleagues41 evaluated groups of un-infected and Candida
albicans-infected rabbits treated with AmBisome and the other
commercially formulation of amphotericine B (Amphotec

),
showing AmBisome treatment able to completely clear Candida
830 albicans from the brain of infected animals. Several years ago,
Albert and colleagues5 described a mouse model of meningitis
caused by Cryptococcus neoformans; also in this case, the AmBi-
some therapy (20 and 30 mg/kg) produced a disappearance of
Cryptococcus in the brain. Several years later, Takemoto and co-
835 workers113 treated the same animal model with a lower dose of
Ambisome (10 mg/kg) in comparison with other antifungal
drugs as fungizone. AmBisome exhibited greater efficacy and,
more importantly, it is distributed into the brain as the penetra-
tion enhanced by the progression of cryptococcal meningitis cor-
840 relating with the in vivo activity. Clemons and colleagues
administered AmBisome to treat different brain infections: in a
first study, AmBisome was compared with other drugs (as flucon-
azole or amphotericin B alone) to treat coccidioidal meningitis in
rabbits. The animal model was represented by immune-sup-
845 pressed rabbits, challenged intra-cisternally with Coccidioides
immitis23 Recently, the authors studied the efficacy of AmBi-
some, micafungin (MICA), caspofungin (CAS), amphotericin B,
voriconazole (VCZ), given alone or in combination, after admin-
istration in immune-suppressed mice, infected intracerebrally
850 with Aspergillus fumigates. In the first study, the brain infection
was significantly reduced by Ambisome treatment if compared
with fluconazole and amphotericine B treatments. On the con-
trary, only the combination therapy at suboptimal doses of
AmBisome and VCZ improved the outcome in CNS aspergillo-
855 sis.22 Thus, AmBisome seems to have an important role in treat-
ing brain infections, in which the inflammation, due to
pathogens, alters the permeability of BBB; in fact AmBisome
could allow to deliver high and active concentrations of drug in
the tissue, reducing or eradicating the fungal burden.
860 Only in the last two years, polymeric NPs were investigated as
an alternative treatment in brain infection diseases. Liu and cow-
orkers tested a new kind of NPs in rabbit models to treat the
brain infections disease. Amphiphilic cholesterol-conjugated
G3R6TAT peptide (CG3R6TAT), which contains TAT
865 sequence, was designed and assembled into core/shell NPs. These
NPs possessed a broad spectrum of strong antimicrobial activi-
ties, much stronger than the hydrophilic peptide, incapable of
forming NPs. The Nps were firstly examined for in vivo activity
against Staphylococcus Aureus in comparison with vancomycin,
870 a therapeutic agent widely used for the prophylaxis, suppression,
and treatment of S. Aureus meningitis. The NPs were found to
be as efficient as vancomycin in treating the meningitis in rabbits
(Liu at al., 2009). In another experiment, CG3R6TAT NPs
showed a good antimicrobial activity against the brain infections
875caused by Cryptococcus neoformans in rabbit model, in which
the meningitis was induced inoculating intracisternally the yeast
suspension. The authors demonstrated that the NPs crossed the
BBB and suppressed the yeast growth in the brain tissues with
similar efficiency as amphotericin B did.121 They hypothesized
880that cationic peptide-decorated NPs may be taken up by the
BBB through adsorptive endocytosis, diffusing into the brain tis-
sue and suppressing bacterial growth in the brain.
Finally, starting from the hypothesis that37,58 in NPs coated
with polisorbate 80 seem to be uptaken by the brain capillary
885endothelial cells due to specific interaction with LDL receptors,
Ren and co-workers prepared polysorbate 80 coated amphoteri-
cin B/PLA-b-PEG NPs to target cryptococcal meningitis-bearing
mice. The results confirmed the therapeutic efficacy of these for-
mulations in fungal infection in the brain, decreasing the speed
890of colony growth and the count of colony, thus increasing the
survival time of animals.92
Conclusion
The interest in developing targeted systems, able to reach the
CNS, represented one of major section of neuroscience, over the
895last 20 y The pathologies affecting the “Brain” are surely the
most difficult to be treated and the less favorable in term of res-
cue of the integrity of the neuronal structures. These pathologies,
meaning gliomas, PD and AD, neurodegenerative diseases as
MS, or infectious and stroke diseases, all have similar features,
900which are common and could represent a possible target for
innovative therapies. Moreover, the presence of the BBB is usu-
ally a great limitation for drugs, which are normally unable to
enter in the CNS.
Thus, the application of nanotechnology to CNS diseases
905(namely Nano-Neuroscience) is surely representing one of the
most innovative strategy to improve the current treatments and,
possibly, to find newer and, most of all, more efficacious thera-
pies. Both NPs and LPs have been deeply investigated with sev-
eral in vitro and in vivo models. In this review, we tried to
910summarize the most interesting and valuable in vivo evidences,
since we do consider extremely risky to translate in vitro results
(on BBB co-coltures) to in vivo outlooks of efficacy.
Moreover, in some of the cited pathologies, the integrity of
BBB is seriously compromised, such as in glioma or stroke, as
915well as in other diseases, like in AD and PD, the permeability
across the inflamed BBB is actually implemented. In these cases,
a brain targeting has not to be considered as BBB crossing goal,
but better as “pathology-targeted” aim.
Several experiments on polymeric NPs and LPs have been
920reviewed considering a general aim of understanding both the
rate of brain delivery and the biodistribution; in particular, the
last aim is pivotal for the scale-up of neuro-nanomedicine, since
scientists must strongly assess both brain delivery efficiency and
safety of nanocarriers. Moreover, beside a number of proof-of-
925concept experiments, relatively few pre-clinical data have been
reached by using in vivo models (mice and rats, mainly), assessing
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the efficacy against brain disease of active molecules (gene, drugs,
enzyme, etc..) by means of nanocarrier-mediated delivery. These
results pointed out a batch of data which would be useful for
930 improving, developing and finalizing this new, non-invasive and
efficacious strategy for the treatment of the brain diseases, such as
AD and PD, gliomas, infectious disease, MS and LSD.
A final remark should be given regarding the possible develop-
ment of nanocarriers for CNS and hopefully to drive a complete
935 research project for neuro-nanomedicine.
Firstly, the choice of biodegradable and biocompatible start-
ing materials is pivotal in speeding up the acceptability and FDA
approval of new nanocarriers; secondly, the targeting strategy
(meaning surface engineering with CNS targeting ligands) should
940 be chosen in function of the pathology, since the BBB integrity
and permeability is varying from disease to disease. It could be
possible that the need for BBB crossing would not be required,
especially in the case of stroke and gliomas, while it is fundamen-
tal in other BBB-healthy pathologies (such as AD or MS). Third,
945the choice of the carriers should be considered as function of the
kind of drugs to be delivered: in particular, polymeric NPs could
be useful in both hydrophilic and hydrophobic active substance
encapsulation, while LPs would better contribute to an effective
gene therapy. Finally, the overall fate of carriers and, most of all,
950their stability in the bloodstream should be accurately investi-
gated a-priori and the proper corrections and tricks should be
taken in great consideration, to definitively allow nanocarriers to
exploit their job at their best.
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